Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping
Sylvan C. Baca(Broad Institute), Matthew L. Freedman(Brigham and Women's Hospital), Jerome Ritz(Dana-Farber Cancer Institute), Keith L. Ligon(Brigham and Women's Hospital), Manisha Thakuria(Brigham and Women's Hospital), Melissa E. Hughes(Dana-Farber Cancer Institute), Mark M. Pomerantz(Dana-Farber Cancer Institute), Ji-Heui Seo(Dana-Farber Cancer Institute), Patrick Y. Wen(Dana-Farber Cancer Institute), Zoltán Szállási(Semmelweis University), Catherine B. Meador(Vanderbilt University Medical Center), John Canniff(Dana-Farber Cancer Institute), Talal El Zarif(Yale University), Yijia Jiang(Dana-Farber Cancer Institute), Rong Li(Guangxi Medical University), Xintao Qiu(Dana-Farber Cancer Institute), Miklós Dióssy(Boston Children's Hospital), Nancy U. Lin(Dana-Farber Cancer Institute), Renée Maria Saliby(Yale University), Toni K. Choueiri(Harvard University), Len Taing(Dana-Farber Cancer Institute), Karl Semaan(Broad Institute), Tim F. Greten(National Cancer Institute), Matthew G. Oser(Harvard University), Jacob E. Berchuck(Dana-Farber Cancer Institute), Henry W. Long(Dana-Farber Cancer Institute), Matthew P. Davidsohn(Dana-Farber Cancer Institute), Sara M. Tolaney(Harvard University), Brad Fortunato(Broad Institute), Kimmie Ng(Dana-Farber Cancer Institute), William D. Figg(National Cancer Institute), James A. DeCaprio(Harvard University), Arun Rajan(National Cancer Institute), F. Stephen Hodi(Harvard University), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Aaron N. Hata(Harvard University), Heather A. Parsons(Harvard University), Hunter Savignano(Dana-Farber Cancer Institute), Ziwei Zhang(State Administration of Traditional Chinese Medicine of the People's Republic of China), Cindy H. Chau(National Institutes of Health), Ikenna Madueke(Dana-Farber Cancer Institute), Shahabbedin Sotudian(Broad Institute), Gitanjali Lakshminarayanan(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k